524717 TITANBIO

Titan Biotech Share Price

₹779.95 +20.7 (2.73%)

04 Jan, 2025 15:43

SIP TrendupStart SIP in TITANBIO

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -1.35%
  • Over 3 Month + 9.53%
  • Over 6 Month + 27.93%
  • Over 1 Year + 90.19%
SIP Lightning

Smart Investing Starts Here Start SIP with Titan Biotech for Steady Growth!

Invest Now

Titan Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Titan Biotech Financials

Titan Biotech Technicals

EMA & SMA

Current Price
₹779.95
+ 20.7 (2.73%)
pointer
  • stock-down_img
  • Bullish Moving Average 14
  • stock-up_img
  • Bearish Moving Average 2
  • 20 Day
  • ₹768.81
  • 50 Day
  • ₹779.96
  • 100 Day
  • ₹746.61
  • 200 Day
  • ₹668.84

Resistance and Support

779.65 Pivot Speed
  • R3 841.30
  • R2 820.65
  • R1 800.30
  • S1 759.30
  • S2 738.65
  • S3 718.30

What's your outlook on Titan Biotech?

You can only vote for once

Titan Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-29 Audited Results
2024-02-12 Quarterly Results
2023-11-08 Quarterly Results

Titan Biotech F&O

Titan Biotech Shareholding Pattern

No data available.

About Titan Biotech

  • NSE Symbol
  • TITANBIO
  • BSE Symbol
  • 524717
  • ISIN
  • INE150C01011

Similar Stocks to Titan Biotech

Titan Biotech FAQs

Titan Biotech share price is ₹779 As on 04 January, 2025 | 15:29

The Market Cap of Titan Biotech is ₹644.5 Cr As on 04 January, 2025 | 15:29

The P/E ratio of Titan Biotech is 25.5 As on 04 January, 2025 | 15:29

The PB ratio of Titan Biotech is 4.8 As on 04 January, 2025 | 15:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23